Table 1.

Age, diagnosis, karyotype, and best response.

Age	Diagnosis	Karyotype	% Bone Marrow Blasts	R-IPSS Score and Category for Primary MDS Patients	Bortezomib Dose (mg/m2)	# cycles	Best Response, Time to Best Response (cycles)	Duration of Best Response, (months)	Prior treatment(s) (excluding GFs)	Prior hypomethylating agent	Proceeded to SCT
73	t-MDS	−7	2		0.7	2	SD, 1	4	For MDS: azacitidine X 5, then lenalidomide For lung cancer: Chemotherapy and XRT	A
67	RAEB-2	NL	11	6.5, Very high	0.7	7	mCR, 3	6			Y
76	RAEB-2	NL	16	5.5, High	0.7	7	CR, 3
81	RAEB-2	complex	10	8.5, Very high	1	2	NR
87	RAEB-1	−7	8		1	3	NR		decitabine	D
74	t-MDS	del(20q), −7	8		1	2	PCyR, 2	3	prior treatment for APML		Y
79	RAEB-2	del(5q) with additional complex	11		1	2	NR		lenalidomide X 5 years for del5q MDS
75	MDS/MPN	NL	4	2.5, Low	1	2	NR		hydroxyurea for HES
73	RAEB-2	NL				0*	removed
67	RAEB-2	−Y	10	3, Low	1	1	NR				Y
78	RCMD	del(5q), del(20q)	2	3, Low	1.3	9	PCyR, 3	3
62	t-CMML	t(11;19)	2		1.3	3	NR
63	CMML-2	NL	14	5, High	1.3	3	NR
78	AML	NL (FLT3 ITD+, NPM1 +)	67		1.3	1	NR
58	AML	NL	89		1.3	2	NR		multiple chemotherapies for AML, SCT	D
63	AML	del(5q) with additional complex	90		1.3	3	NR		decitabine, RIC SCT	D
79	AML	del(12p)	40		1.3	1	NR		hydroxyurea for CMML
64	RARS	complex	2		1.3	9	CCyR, 3	15 (persists)	azacitidine, lenalidomide, thalidomide	A
72	AML	i(11)	40		1.3	6	CR, 3	3
72	t-AML	−7	15		1.3	2	NR		For AML: AML induction, azacitidine X 8 For LPL: fludarabine	A
54	AML	NL	38		1.3	1	NR		AML induction, SCT, azacitidine	A
54	AML	t(3;3)	60		1.3	2	NR		multiple prior inductions
78	AML	NL	45		1.3	1	NR		decitabine X 8 cycles	D

^*= removed prior to start due to rapidly progressive disease, GFs = growth factors, t-MDS = therapy-related MDS, t-AML = therapy-related AML, mCR = marrow complete remission, PCyR = partial cytogenetic response, CCyR = complete cytogenetic response, NR = no response, CR = complete remission, HES = hypereosinophilic syndrome, APML = acute promyelocytic leukemia. A=azacitidine, D=decitabine.